Enter a valid recipient name
Enter a valid recipient email address
Enter a valid name
Enter a valid email address

Genentech, a member of the Roche Group, is aggressively researching ADCs because this therapeutic option may have the potential to treat cancer and improve patients’ lives.1

ResearchADCs is a central resource for medical professionals, students, and basic and translational researchers with an interest in learning more about ADCs and their role in cancer therapy.

The potential of ADCs

The development of an ADC

Components of ADCs

Mechanism of action of ADCs

1.

Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005;23:1137-1146.